<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug felbamate has demonstrated efficacy against a variety of <z:hpo ids='HP_0001250'>seizure</z:hpo> types in the pediatric population, particularly <z:hpo ids='HP_0001250'>seizures</z:hpo> associated with <z:e sem="disease" ids="C0238111" disease_type="Disease or Syndrome" abbrv="">Lennox-Gastaut syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Postmarketing experience, however, revealed serious idiosyncratic adverse effects not observed during clinical trials, including <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and <z:hpo ids='HP_0001399'>liver failure</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>As a result, many physicians have been hesitant to prescribe felbamate </plain></SENT>
<SENT sid="3" pm="."><plain>This retrospective study evaluated the efficacy of felbamate in a pediatric population with <z:e sem="disease" ids="C1096063" disease_type="Disease or Syndrome" abbrv="">intractable epilepsy</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Of 38 patients, 22 had <z:e sem="disease" ids="C0238111" disease_type="Disease or Syndrome" abbrv="">Lennox-Gastaut syndrome</z:e> (58%); 6 had <z:e sem="disease" ids="C0393702" disease_type="Disease or Syndrome" abbrv="">myoclonic-astatic epilepsy</z:e> of Doose (16%); 5 had <z:e sem="disease" ids="C0270854" disease_type="Disease or Syndrome" abbrv="">symptomatic generalized epilepsy</z:e>, not otherwise specified (13%); and 5 had symptomatic <z:e sem="disease" ids="C0014547" disease_type="Disease or Syndrome" abbrv="">localization-related epilepsy</z:e> (13%) </plain></SENT>
<SENT sid="5" pm="."><plain>Most patients had multiple <z:hpo ids='HP_0001250'>seizure</z:hpo> types and had been tried on a variety of <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> medications </plain></SENT>
<SENT sid="6" pm="."><plain>With felbamate treatment, 6 patients (16%) became <z:hpo ids='HP_0001250'>seizure</z:hpo> free, including 4 of the 6 patients with <z:e sem="disease" ids="C0393702" disease_type="Disease or Syndrome" abbrv="">myoclonic-astatic epilepsy</z:e> of Doose; 24 patients (63%) had a greater than 50% reduction in <z:hpo ids='HP_0001250'>seizure</z:hpo> frequency </plain></SENT>
<SENT sid="7" pm="."><plain>In this population felbamate appeared to be safe, with minimal adverse effects </plain></SENT>
<SENT sid="8" pm="."><plain>The study is limited by the small number of patients and by its retrospective nature, but nonetheless adds to the evidence that felbamate is an important <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drug for medically refractory <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in children and is well tolerated with few adverse effects </plain></SENT>
</text></document>